About 50% of papillary thyroid carcinomas (PTC) harbor activating mutations in the BRAF gene (mostly BRAFV600E), an effector of MEK that in turn activates the ERK1 and ERK2 mitogen-activated protein kinases (Review [9,10]). The gene discussed is BRAF; the disease is differentiated thyroid carcinoma.